Latest news with #StockAnalysis
Yahoo
a day ago
- Business
- Yahoo
Is McKesson (MCK) Outperforming Other Medical Stocks This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. McKesson (MCK) is a stock that can certainly grab the attention of many investors, but do its recent returns compare favorably to the sector as a whole? By taking a look at the stock's year-to-date performance in comparison to its Medical peers, we might be able to answer that question. McKesson is a member of the Medical sector. This group includes 999 individual stocks and currently holds a Zacks Sector Rank of #4. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group. The Zacks Rank emphasizes earnings estimates and estimate revisions to find stocks with improving earnings outlooks. This system has a long record of success, and these stocks tend to be on track to beat the market over the next one to three months. McKesson is currently sporting a Zacks Rank of #2 (Buy). The Zacks Consensus Estimate for MCK's full-year earnings has moved 1.4% higher within the past quarter. This signals that analyst sentiment is improving and the stock's earnings outlook is more positive. Our latest available data shows that MCK has returned about 26.6% since the start of the calendar year. Meanwhile, stocks in the Medical group have lost about 4.9% on average. This means that McKesson is performing better than its sector in terms of year-to-date returns. Another stock in the Medical sector, Adagene Inc. Sponsored ADR (ADAG), has outperformed the sector so far this year. The stock's year-to-date return is 4.8%. In Adagene Inc. Sponsored ADR's case, the consensus EPS estimate for the current year increased 7.9% over the past three months. The stock currently has a Zacks Rank #2 (Buy). To break things down more, McKesson belongs to the Medical - Dental Supplies industry, a group that includes 14 individual companies and currently sits at #84 in the Zacks Industry Rank. Stocks in this group have lost about 1.9% so far this year, so MCK is performing better this group in terms of year-to-date returns. In contrast, Adagene Inc. Sponsored ADR falls under the Medical - Biomedical and Genetics industry. Currently, this industry has 503 stocks and is ranked #75. Since the beginning of the year, the industry has moved -2.9%. Investors interested in the Medical sector may want to keep a close eye on McKesson and Adagene Inc. Sponsored ADR as they attempt to continue their solid performance. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report McKesson Corporation (MCK) : Free Stock Analysis Report Adagene Inc. Sponsored ADR (ADAG) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Sign in to access your portfolio
Yahoo
5 days ago
- Business
- Yahoo
NetApp Q1 Outlook Falls Short, Analyst Lowers Price Forecast
NetApp, Inc. (NASDAQ:NTAP) reported fiscal fourth-quarter results on Thursday. The company reported quarterly sales of $1.73 billion (+4% year over year), beating the Street view of $1.72 billion. The company reported adjusted earnings per share of $1.93, beating the analyst consensus estimate of $1.90. Following the results, Wells Fargo analyst Aaron Rakers maintains NetApp with an Equal Weight rating, lowering the price forecast from $115 to $ analyst David Vogt reiterated the Neutral rating on the stock, decreasing the price forecast from $115 to $108. In the fourth quarter, Hybrid Cloud segment revenue rose to $1.57 billion, up from $1.52 billion in the fourth quarter of fiscal 2024. Public Cloud segment revenue reached $164 million, compared to $152 million in the prior-year quarter. Quarterly billings reached $2.03 billion, up from $1.81 billion in the fourth quarter of fiscal 2024, marking a 12% year-over-year increase. The company reported operating cash flow of $675 million, compared to $613 million in the fourth quarter of fiscal year 2024. The company reported cash and equivalents of $3.85 billion at the end of the fourth quarter of fiscal year 2025. In the fourth quarter, NetApp returned $355 million to its stockholders through a combination of share repurchases and cash dividends, it said in a press release. According to George Kurian, CFO of NetApp, fiscal year 2025 saw numerous revenue and profitability records for NetApp. This success was attributed to significant market share gains in all-flash storage and the accelerating growth of their first-party and marketplace storage services. Kurian also noted the company's strategic moves during the year, including a refresh of their entire systems portfolio, a sharper focus on cloud services, and positioning to lead in the enterprise AI market. Looking ahead to fiscal year 2026, he expressed confidence in continued long-term growth, citing the company's strongest portfolio to date, a differentiated value proposition, and ongoing innovation and market expansion following a year of market share gains. NetApp expects first-quarter adjusted EPS to range between $1.48 and $1.58, below the $1.65 estimate. The company forecasts first-quarter revenue between $1.455 billion and $1.605 billion, compared to the $1.61 billion consensus. NetApp projects FY2026 adjusted EPS between $7.60 and $7.90, compared to the $7.72 estimate. The company expects revenue between $6.625 billion and $6.875 billion, versus the $6.86 billion consensus. Price Action: NTAP shares are trading lower by 0.51% to $98.71 at last check Friday. Read Next:Photo via Shutterstock Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market. Get the latest stock analysis from Benzinga? NETAPP (NTAP): Free Stock Analysis Report This article NetApp Q1 Outlook Falls Short, Analyst Lowers Price Forecast originally appeared on © 2025 Benzinga does not provide investment advice. All rights reserved. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
6 days ago
- Business
- Yahoo
UiPath (PATH) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
UiPath (PATH) reported $356.62 million in revenue for the quarter ended April 2025, representing a year-over-year increase of 6.4%. EPS of $0.11 for the same period compares to $0.13 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $332.33 million, representing a surprise of +7.31%. The company delivered an EPS surprise of +10.00%, with the consensus EPS estimate being $0.10. While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health. As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. Here is how UiPath performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: ARR: $1.69 billion versus $1.69 billion estimated by three analysts on average. Net New ARR: $27 million versus the three-analyst average estimate of $22.09 million. Dollar based net retention rate: 108% versus the two-analyst average estimate of 109.6%. Revenue- Licenses: $128.29 million compared to the $115.46 million average estimate based on four analysts. The reported number represents a change of -8.5% year over year. Revenue- Professional Services and other: $11.04 million versus the four-analyst average estimate of $9.68 million. Revenue- Subscription services: $217.30 million compared to the $207.27 million average estimate based on four analysts. View all Key Company Metrics for UiPath here>>>Shares of UiPath have returned +8.4% over the past month versus the Zacks S&P 500 composite's +6.7% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report UiPath, Inc. (PATH) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
Yahoo
7 days ago
- Business
- Yahoo
Synopsys (SNPS) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
For the quarter ended April 2025, Synopsys (SNPS) reported revenue of $1.6 billion, up 10.3% over the same period last year. EPS came in at $3.67, compared to $3.00 in the year-ago quarter. The reported revenue compares to the Zacks Consensus Estimate of $1.6 billion, representing a surprise of +0.16%. The company delivered an EPS surprise of +8.26%, with the consensus EPS estimate being $3.39. While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance. Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance. Here is how Synopsys performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts: Revenue- Maintenance and service: $265.26 million versus $279.24 million estimated by four analysts on average. Compared to the year-ago quarter, this number represents a -4.1% change. Revenue- Total products revenue: $1.34 billion compared to the $1.32 billion average estimate based on four analysts. The reported number represents a change of +13.7% year over year. Revenue by segment- Design IP: $482 million compared to the $443.37 million average estimate based on three analysts. The reported number represents a change of +20.6% year over year. Revenue by segment- Design Automation: $1.12 billion compared to the $1.16 billion average estimate based on three analysts. The reported number represents a change of +6.4% year over year. Revenue- Upfront products: $510.68 million versus the three-analyst average estimate of $415.15 million. The reported number represents a year-over-year change of +28.8%. Revenue- Time-based products: $828.33 million compared to the $904.12 million average estimate based on three analysts. The reported number represents a change of +6% year over year. View all Key Company Metrics for Synopsys here>>>Shares of Synopsys have returned +11.1% over the past month versus the Zacks S&P 500 composite's +7.4% change. The stock currently has a Zacks Rank #3 (Hold), indicating that it could perform in line with the broader market in the near term. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Synopsys, Inc. (SNPS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-05-2025
- Business
- Yahoo
TKOMY or WRB: Which Is the Better Value Stock Right Now?
Investors with an interest in Insurance - Property and Casualty stocks have likely encountered both Tokio Marine Holdings Inc. (TKOMY) and W.R. Berkley (WRB). But which of these two stocks offers value investors a better bang for their buck right now? We'll need to take a closer look. We have found that the best way to discover great value opportunities is to pair a strong Zacks Rank with a great grade in the Value category of our Style Scores system. The Zacks Rank favors stocks with strong earnings estimate revision trends, and our Style Scores highlight companies with specific traits. Tokio Marine Holdings Inc. and W.R. Berkley are sporting Zacks Ranks of #2 (Buy) and #3 (Hold), respectively, right now. The Zacks Rank favors stocks that have recently seen positive revisions to their earnings estimates, so investors should rest assured that TKOMY has an improving earnings outlook. But this is only part of the picture for value investors. Value investors also try to analyze a wide range of traditional figures and metrics to help determine whether a company is undervalued at its current share price levels. The Style Score Value grade factors in a variety of key fundamental metrics, including the popular P/E ratio, P/S ratio, earnings yield, cash flow per share, and a number of other key stats that are commonly used by value investors. TKOMY currently has a forward P/E ratio of 10.64, while WRB has a forward P/E of 17.43. We also note that TKOMY has a PEG ratio of 0.71. This popular metric is similar to the widely-known P/E ratio, with the difference being that the PEG ratio also takes into account the company's expected earnings growth rate. WRB currently has a PEG ratio of 2.54. Another notable valuation metric for TKOMY is its P/B ratio of 2.47. The P/B ratio is used to compare a stock's market value with its book value, which is defined as total assets minus total liabilities. For comparison, WRB has a P/B of 3.15. These are just a few of the metrics contributing to TKOMY's Value grade of B and WRB's Value grade of C. TKOMY sticks out from WRB in both our Zacks Rank and Style Scores models, so value investors will likely feel that TKOMY is the better option right now. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Tokio Marine Holdings Inc. (TKOMY) : Free Stock Analysis Report W.R. Berkley Corporation (WRB) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
